You are here

Article info

Article menu

Download PDFPDF

Treatments
Editorial
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

Authors

  • Eric Toussirot INSERM CIC-1431, Clinical Investigation Center in Biotherapy, University Hospital of Besançon, Besançon, France Fédération Hospitalo-Universitaire INCREASE, University Hospital of Besançon, Besançon, France Department of Rheumatology, University Hospital of Besançon, Besançon, France Department of Therapeutics and EPILAB EA4266, University of Bourgogne Franche-Comté, Epigénétique des Infections Virales et des Maladies Inflammatoires, Besançon, France PubMed articlesGoogle scholar articles
  • Hubert Marotte SAINBIOSE INSERM U1059, University of Lyon, Saint-Etienne, France Department of Rheumatology, Hôpital Nord, University Hospital, Saint-Etienne, France PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Eric Toussirot; etoussirot{at}chu-besancon.fr
View Full Text

Citation

Toussirot E, Marotte H
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
RMD Open 2017;3:e000492. doi: 10.1136/rmdopen-2017-000492

Publication history

  • Received May 6, 2017
  • Revision received July 4, 2017
  • Accepted July 17, 2017
  • First published September 12, 2017.
Online issue publication 
July 06, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/